FMFiras Mourtada

Firas Mourtada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Firas Mourtada has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Justin Mikell

    Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA

    2 shared publications
  • Adam Cunha

    Department of Radiation Oncology, University of California-San Francisco, CA

    1 shared publication
  • Adam P Dicker

    Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

    1 shared publication
  • Adam Raben

    Department of Radiation Oncology, Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE, USA

    1 shared publication
  • Andrea Molineu

    1 shared publication
  • Antonio L. Damato

    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY

    1 shared publication

Latest Publications

  • Open Access

    The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules

    by Kimberly M Arnold, Nicole J Flynn, Adam Raben, Lindsay Romak, Yan Yu, Adam P Dicker, Firas Mourtada, Jennifer Sims-Mourtada

    In addition to inducing lethal DNA damage in tumor and stromal cells, radiation can alter the interactions of tumor cells with their microenvironment. Recent technological advances in planning and delivery of external beam radiotherapy have allowed delivery of larger doses per fraction (hypofractionation) while minimizing dose to normal tissues with higher precision. The effects of radiation on the tumor microenvironment vary with dose and fractionation schedule. In this review, we summarize the effects of conventional and hypofractionated radiation regimens on the immune system and tumor stroma. We discuss how these interactions may provide therapeutic benefit in combination with targeted therapies. Understanding the differential effects of radiation dose and fractionation can have implications for choice of combination therapies.


  • Magnetic resonance imaging basics for the prostate brachytherapist

    by Jihong Wang, Kari Tanderup, Adam Cunha, Antonio L. Damato, Gil'AD N. Cohen, Rajat J. Kudchadker, Firas Mourtada


  • Open Access

    Evaluation of a deterministic grid-based Boltzmann solver (GBBS) for voxel-level absorbed dose calculations in nuclear medicine

    by Justin Mikell, S Cheenu Kappadath, Todd Wareing, William D Erwin, Uwe Titt, Firas Mourtada

    To evaluate the 3D Grid-based Boltzmann Solver (GBBS) code ATTILA ® for coupled electron and photon transport in the nuclear medicine energy regime for electron (beta, Auger and internal conversion electrons) and photon (gamma, x-ray) sources. Codes rewritten based on ATTILA are used clinically for both high-energy photon teletherapy and 192Ir sealed source brachytherapy; little information exists for using the GBBS to calculate voxel-level absorbed doses in nuclear medicine. We compared DOSXYZnrc Monte Carlo (MC) with published voxel-S-values to establish MC as truth. GBBS was investigated for mono-energetic 1.0, 0.1, and 0.01 MeV electron and photon sources as well as 131I and 90Y radionuclides. We investigated convergence of GBBS by analyzing different meshes (), energy group structures () for each radionuclide component, angular quadrature orders (, and scattering order expansions (–); higher indices imply finer discretization. We compared GBBS to MC in (1) voxel-S-value geometry for soft tissue, lung, and bone, and (2) a source at the interface between combinations of lung, soft tissue, and bone. Excluding Auger and conversion electrons, MC agreed within ≈5% of published source voxel absorbed doses. For the finest discretization, most GBBS absorbed doses in the source voxel changed by less than 1% compared to the next finest discretization along each phase space variable indicating sufficient convergence. For the finest discretization, agreement with MC in the source voxel ranged from −3% to −20% with larger differences at lower energies (−3% for 1 MeV electron in lung to −20% for 0.01 MeV photon in bone); similar agreement was found for the interface geometries. Differences between GBBS and MC in the source voxel for 90Y and 131I were −6%. The GBBS ATTILA was benchmarked against MC in the nuclear medicine regime. GBBS can be a viable alternative to MC for voxel-level absorbed doses in nuclear medicine. However, reconciliation of the differences between GBBS and MC at lower energies requires further investigation of energy deposition cross-sections.


  • Dosimetric impact of Acuros XB deterministic radiation transport algorithm for heterogeneous dose calculation in lung cancer

    by Tao Han, David Followill, Justin Mikell, Roman Repchak, Andrea Molineu, Rebecca Howell, Mohammad Salehpour, Firas Mourtada

    Purpose:: The novel deterministic radiation transport algorithm, Acuros XB (AXB), has shown great potential for accurate heterogeneous dose calculation. However, the clinical impact between AXB and other currently used algorithms still needs to be elucidated for translation between these algorithms. The purpose of this study was to investigate the impact of AXB for heterogeneous dose calculation in lung cancer for intensity‐modulated radiation therapy (IMRT) and volumetric‐modulated arc therapy (VMAT).Methods:: The thorax phantom from the Radiological Physics Center (RPC) was used for this study. IMRT and VMAT plans were created for the phantom in the Eclipse 11.0 treatment planning system. Each plan was delivered to the phantom three times using a Varian Clinac iX linear accelerator to ensure reproducibility. Thermoluminescent dosimeters (TLDs) and Gafchromic EBT2 film were placed inside the phantom to measure delivered doses. The measurements were compared with dose calculations from AXB 11.0.21 and the anisotropic analytical algorithm (AAA) 11.0.21. Two dose reporting modes of AXB, dose‐to‐medium in medium (Dm,m) and dose‐to‐water in medium (Dw,m), were studied. Point doses, dose profiles, and gamma analysis were used to quantify the agreement between measurements and calculations from both AXB and AAA. The computation times for AAA and AXB were also evaluated.Results:: For the RPC lung phantom, AAA and AXB dose predictions were found in good agreement to TLD and film measurements for both IMRT and VMAT plans. TLD dose predictions were within 0.4%–4.4% to AXB doses (bothDm,m and Dw,m); and within 2.5%–6.4% to AAA doses, respectively. For the film comparisons, the gamma indexes (±3%/3 mm criteria) were 94%, 97%, and 98% for AAA, AXB_Dm,m, and AXB_Dw,m, respectively. The differences between AXB and AAA in dose–volume histogram mean doses were within 2% in the planning target volume, lung, heart, and within 5% in the spinal cord. However, differences up to 8% between AXB and AAA were found at lung/soft tissue interface regions for individual IMRT fields. AAA was found to be 5–6 times faster than AXB for IMRT, while AXB was 4–5 times faster than AAA for VMAT plan.Conclusions:: AXB is satisfactorily accurate for the dose calculation in lung cancer for both IMRT and VMAT plans. The differences between AXB and AAA are generally small except in heterogeneous interface regions. AXBDw,m and Dm,m calculations are similar inside the soft tissue and lung regions. AXB can benefit lung VMAT plans by both improving accuracy and reducing computation time.